Karyopharm Therapeutics Inc. (KPTI) Stock Price

KPTIStock

$1.92−70.48%52W

Market Cap$43.55M

P/E—

PEG Ratio—

Div yield—

Beta0.97

KPTI Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-91.14%

Price vs S&P 500 (4W)-76.82%

VGM Score50.43

Book Value / Share (Quarterly)$0.68

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-2.40%

Cash Flow / Share (Quarterly)$-2.62

Price vs S&P 500 (YTD)-86.69%

Gross Margin (TTM)96.03%

Net Profit Margin (TTM)-129.02%

EPS (TTM)$-14.84

10-Day Avg Trading Volume1.23M

EPS Excl Extra (TTM)$-14.84

Revenue Growth (5Y)6.21%

EPS (Annual)$-17.93

ROI (Annual)-81.28%

Gross Margin (Annual)95.93%

Net Profit Margin (5Y Avg)-89.84%

Cash / Share (Quarterly)$4.03

Revenue Growth QoQ (YoY)16.83%

ROA (Last FY)-180.82%

Revenue Growth TTM (YoY)6.33%

EBITD / Share (TTM)$-10.22

ROE (5Y Avg)-210.81%

Operating Margin (TTM)-96.99%

Cash Flow / Share (Annual)$-4.12

P/B Ratio0.89x

P/B Ratio (Quarterly)22.52x

Net Income / Employee (Annual)$-859,800

EV / Revenue (TTM)1.66x

Net Interest Coverage (TTM)-3.55x

ROA (TTM)-176.87%

EPS Incl Extra (Annual)$-17.93

Current Ratio (Annual)1.12x

Quick Ratio (Quarterly)0.97x

3-Month Avg Trading Volume1.00M

52-Week Price Return-70.48%

Revenue / Employee (TTM)$662,800

Tangible BV / Share (Quarterly)$-0.88

P/S Ratio (Annual)0.31x

Asset Turnover (Annual)1.35x

52-Week High$10.99

Operating Margin (5Y Avg)-76.47%

EPS Excl Extra (Annual)$-17.93

CapEx CAGR (5Y)-7.53%

26-Week Price Return-79.89%

Quick Ratio (Annual)0.98x

13-Week Price Return-76.92%

Total Debt / Equity (Annual)3.78x

Current Ratio (Quarterly)1.08x

Enterprise Value$250.98M

Revenue / Share Growth (5Y)54.83%

Asset Turnover (TTM)1.37x

Book Value / Share Growth (5Y)-34.14%

Revenue / Employee (Annual)$640,600

Inventory Turnover (Annual)1.36x

Pretax Margin (Annual)-134.18%

Cash / Share (Annual)$3.48

3-Month Return Std Dev166.11%

Gross Margin (5Y Avg)96.70%

Net Income / Employee (TTM)$-855,100

ROE (Last FY)-388.71%

Net Interest Coverage (Annual)-3.32x

EPS Basic Excl Extra (Annual)$-17.93

Receivables Turnover (TTM)5.16x

Total Debt / Equity (Quarterly)3.78x

EPS Incl Extra (TTM)$-14.84

Receivables Turnover (Annual)5.13x

ROI (TTM)-66.32%

P/S Ratio (TTM)0.30x

Pretax Margin (5Y Avg)-89.70%

Revenue / Share (Annual)$13.36

Tangible BV / Share (Annual)$-0.15

Price vs S&P 500 (52W)-88.79%

Year-to-Date Return-74.73%

5-Day Price Return-3.63%

EPS Normalized (Annual)$-17.93

ROA (5Y Avg)-74.72%

Net Profit Margin (Annual)-134.21%

Month-to-Date Return-3.13%

Cash Flow / Share (TTM)$-1.29

EBITD / Share (Annual)$-13.97

Operating Margin (Annual)-104.80%

LT Debt / Equity (Annual)3.78x

ROI (5Y Avg)-79.29%

LT Debt / Equity (Quarterly)3.78x

EPS Basic Excl Extra (TTM)$-14.84

P/B Ratio (Annual)22.52x

Inventory Turnover (TTM)1.43x

Pretax Margin (TTM)-129.01%

Book Value / Share (Annual)$0.68

Price vs S&P 500 (13W)-79.72%

Beta0.97x

Revenue / Share (TTM)$6.86

ROE (TTM)-182.43%

52-Week Low$1.79

vGradeA

gGradeC

mGradeF

vgmGradeC

KPTI Earnings Surprise History

Q2 25-4.07est. -3.91

Q3 25-3.82est. -3.25

Q4 25-2.23est. -2.00

Q1 26-1.24est. -1.44

Q2 26-2.32est. -1.39

KPTI Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.15

4.00

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
KPTIKaryopharm Therapeutics Inc.	A	C	F	$1.92
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Karyopharm Therapeutics Inc.

Karyopharm Therapeutics is a commercial-stage pharmaceutical company specializing in cancer drugs that inhibit nuclear export. The company's lead product, XPOVIO (selinexor), targets exportin 1 (XPO1), preventing the transport of cancer-promoting proteins out of the cell nucleus. This mechanism represents a novel approach to disrupting cancer cell survival.